OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood (2023) Vol. 142, Iss. 10, pp. 878-886
Open Access | Times Cited: 55
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, et al.
Blood (2023) Vol. 142, Iss. 10, pp. 878-886
Open Access | Times Cited: 55
Showing 1-25 of 55 citing articles:
Immune checkpoint blockade in hematological malignancies: current state and future potential
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Prateek Pophali, Juan Carlos Varela, Jacalyn Rosenblatt
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management
Stephen M. Ansell
American Journal of Hematology (2024)
Closed Access | Times Cited: 7
Stephen M. Ansell
American Journal of Hematology (2024)
Closed Access | Times Cited: 7
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects
Charles Milrod, Ari Pelcovits, Thomas Ollila
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Charles Milrod, Ari Pelcovits, Thomas Ollila
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
Sotirios G. Papageorgiou, Thomas Thomopoulos, Athanasios Liaskas, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1917-1917
Open Access | Times Cited: 20
Sotirios G. Papageorgiou, Thomas Thomopoulos, Athanasios Liaskas, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 1917-1917
Open Access | Times Cited: 20
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
Michael P. Randall, Michael A. Spinner
Cancers (2023) Vol. 15, Iss. 18, pp. 4509-4509
Open Access | Times Cited: 11
Michael P. Randall, Michael A. Spinner
Cancers (2023) Vol. 15, Iss. 18, pp. 4509-4509
Open Access | Times Cited: 11
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy
Jessica F. Burlile, K.M. Frechette, William G. Breen, et al.
Blood Advances (2024) Vol. 8, Iss. 5, pp. 1250-1257
Open Access | Times Cited: 4
Jessica F. Burlile, K.M. Frechette, William G. Breen, et al.
Blood Advances (2024) Vol. 8, Iss. 5, pp. 1250-1257
Open Access | Times Cited: 4
Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma
Shiliang Ge, Kylie Lepic, R. Bhindi, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 118-118
Open Access
Shiliang Ge, Kylie Lepic, R. Bhindi, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 118-118
Open Access
Evaluation and preservation of fertility in patients with hematologic malignancies
Xuan Wang, Ruihao Huang, Lei Liu, et al.
Cancer Letters (2025), pp. 217569-217569
Open Access
Xuan Wang, Ruihao Huang, Lei Liu, et al.
Cancer Letters (2025), pp. 217569-217569
Open Access
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice
Cinzia Pellegrini, Beatrice Casadei, Alessandro Broccoli, et al.
Annals of Hematology (2025)
Open Access
Cinzia Pellegrini, Beatrice Casadei, Alessandro Broccoli, et al.
Annals of Hematology (2025)
Open Access
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers
Timothy Voorhees, Eric McLaughlin, Pallawi Torka, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Timothy Voorhees, Eric McLaughlin, Pallawi Torka, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
Theodoros P. Vassilakopoulos, Athanasios Liaskas, Patricio Javier Pereyra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13187-13187
Open Access | Times Cited: 10
Theodoros P. Vassilakopoulos, Athanasios Liaskas, Patricio Javier Pereyra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13187-13187
Open Access | Times Cited: 10
Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
Federica Giannotti, Carmen De Ramón Ortiz, Federico Simonetta, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Federica Giannotti, Carmen De Ramón Ortiz, Federico Simonetta, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center
Ajami Gikandi, Susan Chi, Kee Kiat Yeo, et al.
Cancer Medicine (2024) Vol. 13, Iss. 8
Open Access | Times Cited: 3
Ajami Gikandi, Susan Chi, Kee Kiat Yeo, et al.
Cancer Medicine (2024) Vol. 13, Iss. 8
Open Access | Times Cited: 3
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Wenyue Sun, Shunfeng Hu, Xin Wang
Cancer Communications (2024) Vol. 44, Iss. 9, pp. 1071-1097
Open Access | Times Cited: 3
Wenyue Sun, Shunfeng Hu, Xin Wang
Cancer Communications (2024) Vol. 44, Iss. 9, pp. 1071-1097
Open Access | Times Cited: 3
Jaimal Kothari, Toby A. Eyre, Ali Rismani, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 6, pp. 2273-2281
Open Access | Times Cited: 3
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
Roberto Tamma, Giuseppe Ingravallo, Francesco Gaudio, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2803-2803
Open Access | Times Cited: 8
Roberto Tamma, Giuseppe Ingravallo, Francesco Gaudio, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2803-2803
Open Access | Times Cited: 8
Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
Yazeed Samara, Matthew Mei
Cancers (2022) Vol. 14, Iss. 7, pp. 1738-1738
Open Access | Times Cited: 11
Yazeed Samara, Matthew Mei
Cancers (2022) Vol. 14, Iss. 7, pp. 1738-1738
Open Access | Times Cited: 11
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies
Simonetta Viviani, Anna Vanazzi, Samuele Frassoni, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 4, pp. 460-471
Closed Access | Times Cited: 2
Simonetta Viviani, Anna Vanazzi, Samuele Frassoni, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 4, pp. 460-471
Closed Access | Times Cited: 2
Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma
Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone
Cancers (2024) Vol. 16, Iss. 23, pp. 4070-4070
Open Access | Times Cited: 2
Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone
Cancers (2024) Vol. 16, Iss. 23, pp. 4070-4070
Open Access | Times Cited: 2
Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
Sarah Perdikis-Prati, Semira Sheikh, B Antonin, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1720-1720
Open Access | Times Cited: 4
Sarah Perdikis-Prati, Semira Sheikh, B Antonin, et al.
Biomedicines (2023) Vol. 11, Iss. 6, pp. 1720-1720
Open Access | Times Cited: 4
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin lymphoma in the Era of Immunotherapy
Michael P. Randall, Michael A. Spinner
(2023)
Open Access | Times Cited: 4
Michael P. Randall, Michael A. Spinner
(2023)
Open Access | Times Cited: 4
The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure
Natalie S. Grover, Christopher Dittus, Astha Thakkar, et al.
Hematology (2023) Vol. 2023, Iss. 1, pp. 510-518
Closed Access | Times Cited: 4
Natalie S. Grover, Christopher Dittus, Astha Thakkar, et al.
Hematology (2023) Vol. 2023, Iss. 1, pp. 510-518
Closed Access | Times Cited: 4
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis Diamantopoulos, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 238-238
Open Access | Times Cited: 1
Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis Diamantopoulos, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 238-238
Open Access | Times Cited: 1
Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens
Jacopo Mariotti, Francesca Ricci, Laura Giordano, et al.
Cells (2024) Vol. 13, Iss. 2, pp. 118-118
Open Access | Times Cited: 1
Jacopo Mariotti, Francesca Ricci, Laura Giordano, et al.
Cells (2024) Vol. 13, Iss. 2, pp. 118-118
Open Access | Times Cited: 1
Emerging immunotherapies in the Hodgkin Lymphoma Armamentarium
Michael A. Spinner, Ranjana H. Advani
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 263-275
Open Access | Times Cited: 1
Michael A. Spinner, Ranjana H. Advani
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 3, pp. 263-275
Open Access | Times Cited: 1
